Kenvue Target of Unusually Large Options Trading (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) was the recipient of some unusual options trading activity on Tuesday. Investors bought 106,657 call options on the company. This is an increase of approximately 851% compared to the average daily volume of 11,211 call options.

Kenvue Price Performance

Shares of KVUE stock traded up $0.32 on Thursday, reaching $23.46. 1,378,587 shares of the company were exchanged, compared to its average volume of 18,005,434. Kenvue has a 1 year low of $17.67 and a 1 year high of $23.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50-day moving average price of $22.72 and a 200 day moving average price of $20.62. The company has a market cap of $44.98 billion, a price-to-earnings ratio of 42.05, a P/E/G ratio of 2.15 and a beta of 1.36.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter last year, the business posted $0.31 earnings per share. The business’s quarterly revenue was down .4% compared to the same quarter last year. Equities research analysts forecast that Kenvue will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

Several research firms have commented on KVUE. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. UBS Group increased their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. Finally, Piper Sandler raised their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.64.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Riverview Trust Co acquired a new stake in shares of Kenvue in the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the 3rd quarter worth $35,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares during the period. Studio Investment Management LLC boosted its position in shares of Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after acquiring an additional 845 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new position in shares of Kenvue during the 3rd quarter valued at about $71,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.